Bookbuilding IPO | ₹28 Cr | Listed at NSE SME | Fri, Nov 7, 2025 - Tue, Nov 11, 2025
Curis Lifesciences IPO is a book build issue of ₹27.52 crores. The issue is entirely a fresh issue of 0.22 crore shares of ₹27.52 crore.
Curis Lifesciences IPO bidding started from Nov 7, 2025 and ended on Nov 11, 2025. The allotment for Curis Lifesciences IPO was finalized on Nov 12, 2025. The shares got listed on NSE SME on Nov 14, 2025.
Curis Lifesciences IPO price band is set at ₹128 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,56,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹3,84,000.
Finaax Capital Advisors Private Limited is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is RS Wealth Management Private Limited.
Refer to Curis Lifesciences IPO RHP for detailed Information.
IPO Open
Fri, Nov 7, 2025
IPO Close
Tue, Nov 11, 2025
Issue Price
₹128 per share
Market Cap (Pre-IPO)
₹103.48 Cr
| IPO Date | 7 to 11 Nov, 2025 |
| Listed on | Fri, Nov 14, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹120 to ₹128 |
| Issue Price | ₹128 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 21,50,000 shares (agg. up to ₹28 Cr) |
| Reserved for Market Maker | 1,08,000 shares RS Wealth Management Private Limited (agg. up to ₹1 Cr) |
| Fresh Issue (Ex Market Maker) | 20,42,000 shares (agg. up to ₹26 Cr) |
| Net Offered to Public | 20,42,000 shares (agg. up to ₹26 Cr) |
| Share Holding Pre Issue | 59,34,434 shares |
| Share Holding Post Issue | 80,84,434 shares |
| NSE Symbol | CURIS |
| ISIN | INE1BZN01016 |
Curis Lifesciences IPO comprises a total issue size of 21,50,000 shares. The net offer to the public is 20,42,000 shares, after excluding 1,08,000 shares allotted on a firm basis. Of the Net offer 10,17,000 (49.80%) are allocated to QIB, 3,09,000 (15.13%) allocated to NII 7,16,000 (35.06%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 10,17,000 | 49.80% | 47.30% |
| − Anchor Investor Shares Offered | 6,09,000 | 28.33% | |
| − QIB (Ex. Anchor) Shares Offered | 4,08,000 | 18.98% | |
| NII (HNI) Shares Offered | 3,09,000 | 15.13% | 14.37% |
| − bNII > ₹10L | 2,07,000 | 9.63% | |
| − sNII < ₹10L | 1,02,000 | 4.74% | |
| Retail Shares Offered | 7,16,000 | 35.06% | 33.30% |
| Firm Reservations | |||
| Market Maker Shares Offered | 1,08,000 | 5.02% | |
| Total Shares Offered | 21,50,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,56,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |
Curis Lifesciences IPO raises ₹7.80 crore from anchor investors. Curis Lifesciences IPO Anchor bid date is November 6, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Thu, Nov 6, 2025 |
| Shares Offered | 6,09,000 |
| Anchor Portion (₹ Cr.) | 7.80 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Dec 11, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, Feb 9, 2026 |
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
Curis Lifesciences Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 25% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 56.29 | 42.53 | 33.88 | 29.75 |
| Total Income | 19.51 | 49.65 | 35.87 | 36.42 |
| Profit After Tax | 2.87 | 6.11 | 4.87 | 1.88 |
| EBITDA | 4.24 | 9.54 | 8.39 | 3.28 |
| NET Worth | 19.10 | 16.23 | 5.87 | 1.01 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 | 0.51 |
| Total Borrowing | 15.32 | 15.62 | 17.09 | 16.19 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | 2.44 |
| 2 | Capital Expenditure towards Construction of a Storage Facility | 3.62 |
| 3 | Pre-payment/Repayment of outstanding Secured Loans | 1.86 |
| 4 | Product Registrations in other countries | 2.69 |
| 5 | Funding our Working Capital Requirements | 11.25 |
| 6 | General Corporate Purposes | 2.85 |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt/Equity | 0.96 |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 10.29 | 10.66 |
| P/E (x) | 12.44 | 12.01 |
| Promoter Holding | 92.68% | 68.03% |
| Market Cap | ₹103.48 Cr. |
The Curis Lifesciences IPO is subscribed 74.39 times on November 11, 2025 6:19:59 PM (Day 3). The public issue subscribed 44.28 times in the individual investors category, 96.17 times in the QIB category, and 115.46 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Application |
|---|---|---|---|---|
| QIB (Ex Anchor) | 96.17 | 4,09,000 | 3,93,35,000 | 44 |
| NII* | 115.46 | 3,08,000 | 3,55,63,000 | 5,576 |
| bNII (bids above ₹10L) | 142.74 | 2,06,000 | 2,94,04,000 | |
| sNII (bids below ₹10L) | 60.38 | 1,02,000 | 61,59,000 | |
| Individual Investor | 44.28 | 7,16,000 | 3,17,06,000 | 15,853 |
| Total | 74.39 | 14,33,000 | 10,66,04,000 | 21,473 |
Total Application : 21,473
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manager fees | 0.20 |
| 2 | Fees Payable to Registrar to the Issue | 0.01 |
| 3 | Fees Payable Advertising and Printing Expenses | 0.04 |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | 0.10 |
| 5 | Fees payable to Peer Review Auditor and Legal Advisor | 0.05 |
| 6 | Fees Payable to Market Maker (for Three Year) | 0.12 |
| 7 | Escrow Bank Fees | 0.01 |
| 8 | Others (Fees payable for marketing & distributing expenses, selling commission, brokerage, processing fees, underwriting fees and miscellaneous expenses) | 2.27 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹128.00 |
| Open | ₹146.10 |
| Low | ₹138.80 |
| High | ₹147.90 |
| Last Trade | ₹141.00 |
Lead Manager Reports
Curis Lifesciences IPO is a SME IPO of 21,50,000 equity shares of the face value of ₹10 aggregating up to ₹28 Crores. The issue is priced at ₹128 per share. The minimum order quantity is 1000.
The IPO opens on Fri, Nov 7, 2025, and closes on Tue, Nov 11, 2025.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Curis Lifesciences IPO using UPI as a payment gateway. Zerodha customers can apply in Curis Lifesciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Curis Lifesciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Curis Lifesciences IPO opens on Fri, Nov 7, 2025 and closes on Tue, Nov 11, 2025.
Curis Lifesciences IPO lot size is 1000, and the minimum amount required for application is ₹2,56,000, with 2 lots being the minimum application size.
You can apply in Curis Lifesciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Curis Lifesciences IPO will be done on Wednesday, November 12, 2025, and the allotted shares will be credited to your demat account by Thu, Nov 13, 2025. Check the Curis Lifesciences IPO allotment status.
The Curis Lifesciences IPO listing date is on Fri, Nov 14, 2025.
